Actithera appoints Darshan Dalal as Chief Medical Officer

Esme Needham | December 11, 2025 | Appointment | |  Actithera, chief medical officer 

Actithera has announced the appointment of Dr Darshan Dalal as its new Chief Medical Officer.

Dalal brings over 15 years of leadership experience in oncology and haematology to the role, having, over the course of his career, advanced more than ten radioligands through various stages of development. He has held senior roles at AstraZeneca and Novartis, leading global teams in the development of radioligand therapies (RLTs) and playing a key role in the creation of Pluvicto.

“Actithera has built a truly differentiated platform grounded in rigorous medicinal chemistry, giving rise to RLTs with the potential for superior binding, tumour retention, selectivity and therapeutic index,” Dalal said.

Advertisement

Actithera is a radiopharmaceutical biotechnology company that aims to translate insights in medicinal chemistry into next-generation RLTs. In his new role, Dalal will lead clinical strategy and development as Actithera begins to bring its lead candidate, a fibroblast activation protein (FAP)-targeting RLT, into the clinic.

Dr Andreas Goutopoulos, CEO of Actithera, commented: “Darshan’s track record in progressing radioligand assets from concept to late-stage development aligns perfectly with our ambition to rapidly advance our FAP-targeting and other pipeline assets into the clinic.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content



Pace appoints Ken Beyer as CEO

December 10, 2025